Next Article in Journal
Enhanced HoVerNet Optimization for Precise Nuclei Segmentation in Diffuse Large B-Cell Lymphoma
Next Article in Special Issue
Intrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions—A Review of the Literature
Previous Article in Journal
Cervical Ectopic Pregnancies—Imaging and Endovascular Treatment
Previous Article in Special Issue
Eosinophilic Cells as a Distinct Morphological Feature in BRAFV600E-Mutated Ovarian Serous Borderline Tumors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Interesting Images

Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum

1
Pathology Unit, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy
2
Gynecology & Obstetrics Unit, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy
3
Radiology Unit, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy
4
Academic Unit of Obstetrics and Gynecology, IRCSS Hospital Polyclinic San Martino, 16132 Genoa, Italy
5
Pathology Unit, Department of Diagnostic and Public Health, University of Verona, 37126 Verona, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(15), 1957; https://doi.org/10.3390/diagnostics15151957
Submission received: 4 July 2025 / Revised: 26 July 2025 / Accepted: 29 July 2025 / Published: 4 August 2025
(This article belongs to the Special Issue Pathology and Diagnosis of Gynecologic Diseases, 3rd Edition)

Abstract

Mature teratomas account for approximately 20% of all ovarian tumors identified in pathological studies. Benign or malignant somatic neoplasms developing within teratomas can arise from any tissue in up to 2% of mature cystic teratomas, including low-grade malignant mucinous neoplasms. This report presents the case of a 34-year-old woman with no previous gynecological or general health issues, who was admitted to our Hospital after an asymptomatic pelvic mass was detected during a routine exam. A transvaginal ultrasound revealed a unilateral pelvic mass in the left adnexal region, measuring 8 cm. The CT scan showed a cystic-appearing formation measuring nearly 12 cm, which indented the bladder dome. Final diagnosis indicated a mucinous carcinoma arising from a mucinous borderline lesion within the context of a mature ovarian teratoma. No other involvement or lymphadenopathies were detected on 18FDG-PET CT scan, and the patient is now well and free of recurrences.

Figure 1. Mature teratomas represent approximately 20% of all ovarian tumors identified in pathological studies. Somatic neoplasms that develop within teratomas are either benign or malignant, arising from any tissue present in the teratomas. These somatic neoplasms may be found in up to 2% of mature cystic teratomas, although they are extremely rare in immature teratomas [1,2]. Epithelial neoplasms can occur in up to 2% of dermoid cysts, with squamous cell carcinoma accounting for the majority (approximately 80%) of malignant tumors. They exhibit a high mutational burden, with mutations in the TP53 gene being the most common abnormality [3,4,5]. Adenocarcinoma is the second most common carcinoma in teratomas (7%), while sarcoma accounts for 8%. Melanomas, melanocytic nevi, and basal cell carcinomas are much less common [6]. In the literature, other benign and malignant tumors (usually as single case reports) have also been reported, including sebaceous carcinoma [7], urothelial carcinoma [7], and low-grade malignant mucinous neoplasms [8]. Mucinous ovarian neoplasms associated with teratomas (MONATs) are uncommon neoplasms, with only a few large series published to date [9,10,11]. Histologically, MONATs are a heterogeneous group of neoplasms, conventionally classified as cystoadenoma, borderline mucinous tumor, and mucinous carcinoma [9,10]. The origin of MONATs has been proposed to be either independent of the teratoma (i.e., having a Mullerian-type phenotype) or derived from the germ cell components of the tumor (with a typical intestinal/appendiceal-type phenotype) [11]. MONATs may be associated with pseudomyxoma ovarii and peritonei, although these characteristics are more frequently observed in a metastatic context [8,12,13]. We present the case of a 34-year-old multiparous woman with no previous gynecological or general health issues. She had been regularly undergoing annual gynecological exams and Pap smear tests. In May 2024, she was admitted to our Hospital after an asymptomatic pelvic mass was detected during a gynecological routine examination. During transvaginal ultrasound performed by an expert operator, a unilateral pelvic mass in the left adnexal region was diagnosed. The lesion was a multilocular solid mass (fewer than 10 locules), measuring 80 mm in maximum diameter, with irregular internal margins due to a solid component measuring 14 × 25 mm, containing mixed content, and moderately vascularized at color Doppler (color score 3). No normal ovarian parenchyma was observed; the right ovary and uterus appeared normal, and no signs of ascites or free fluid in Douglas’s pouch were detected. Serum oncological markers—including CA 125, CA 19.9, CEA, CA 15.3, and AFP—were all negative. IOTA adnex model showed an 84.2% risk of benign tumor, a 15.8% risk of malignancy, and a 7.6% risk of a borderline tumor. A surgical path was decided for the patient, a laparoscopic visualization with frozen section of the left adnexa was planned due to the risk of malignancy and borderline tumor diagnosis driven by transvaginal ultrasound examination; the patient was counseled for eventual surgical staging or debulking surgical procedures based on frozen section diagnosis, according to the most recent guidelines [14,15]. A total body computed tomography with a contrast medium was performed before surgery to evaluate the chest and abdomen. The CT scan was performed with a 64-slice Siemens Somatom Definition AS with dedicated software for dose reduction (SAFIRE, software versione syngo CT 2011A (VA40). The exam was performed before and after the administration of the contrast medium. The contrast medium (90 cc 1.5 pro/kg) was Iomeron 400. (A) Coronal and (B) axial viewing of a cystic-appearing formation (measuring 109 × 77 × 123 mm) was reported in the left adnexal region. The cyst appeared as multiloculated with internal septa and an endoluminal solid projection (characterized by post-contrastographic enhancement). (C) On sagittal viewing, the ovarian mass was responsible for the imprint on the bladder dome, without wall infiltration. There were no expansile formations in the right adnexal site. Anteverted-flexed uterus was of regular volume. No free effusion in the abdomen and no other signs of distant metastasis were reported.
Figure 1. Mature teratomas represent approximately 20% of all ovarian tumors identified in pathological studies. Somatic neoplasms that develop within teratomas are either benign or malignant, arising from any tissue present in the teratomas. These somatic neoplasms may be found in up to 2% of mature cystic teratomas, although they are extremely rare in immature teratomas [1,2]. Epithelial neoplasms can occur in up to 2% of dermoid cysts, with squamous cell carcinoma accounting for the majority (approximately 80%) of malignant tumors. They exhibit a high mutational burden, with mutations in the TP53 gene being the most common abnormality [3,4,5]. Adenocarcinoma is the second most common carcinoma in teratomas (7%), while sarcoma accounts for 8%. Melanomas, melanocytic nevi, and basal cell carcinomas are much less common [6]. In the literature, other benign and malignant tumors (usually as single case reports) have also been reported, including sebaceous carcinoma [7], urothelial carcinoma [7], and low-grade malignant mucinous neoplasms [8]. Mucinous ovarian neoplasms associated with teratomas (MONATs) are uncommon neoplasms, with only a few large series published to date [9,10,11]. Histologically, MONATs are a heterogeneous group of neoplasms, conventionally classified as cystoadenoma, borderline mucinous tumor, and mucinous carcinoma [9,10]. The origin of MONATs has been proposed to be either independent of the teratoma (i.e., having a Mullerian-type phenotype) or derived from the germ cell components of the tumor (with a typical intestinal/appendiceal-type phenotype) [11]. MONATs may be associated with pseudomyxoma ovarii and peritonei, although these characteristics are more frequently observed in a metastatic context [8,12,13]. We present the case of a 34-year-old multiparous woman with no previous gynecological or general health issues. She had been regularly undergoing annual gynecological exams and Pap smear tests. In May 2024, she was admitted to our Hospital after an asymptomatic pelvic mass was detected during a gynecological routine examination. During transvaginal ultrasound performed by an expert operator, a unilateral pelvic mass in the left adnexal region was diagnosed. The lesion was a multilocular solid mass (fewer than 10 locules), measuring 80 mm in maximum diameter, with irregular internal margins due to a solid component measuring 14 × 25 mm, containing mixed content, and moderately vascularized at color Doppler (color score 3). No normal ovarian parenchyma was observed; the right ovary and uterus appeared normal, and no signs of ascites or free fluid in Douglas’s pouch were detected. Serum oncological markers—including CA 125, CA 19.9, CEA, CA 15.3, and AFP—were all negative. IOTA adnex model showed an 84.2% risk of benign tumor, a 15.8% risk of malignancy, and a 7.6% risk of a borderline tumor. A surgical path was decided for the patient, a laparoscopic visualization with frozen section of the left adnexa was planned due to the risk of malignancy and borderline tumor diagnosis driven by transvaginal ultrasound examination; the patient was counseled for eventual surgical staging or debulking surgical procedures based on frozen section diagnosis, according to the most recent guidelines [14,15]. A total body computed tomography with a contrast medium was performed before surgery to evaluate the chest and abdomen. The CT scan was performed with a 64-slice Siemens Somatom Definition AS with dedicated software for dose reduction (SAFIRE, software versione syngo CT 2011A (VA40). The exam was performed before and after the administration of the contrast medium. The contrast medium (90 cc 1.5 pro/kg) was Iomeron 400. (A) Coronal and (B) axial viewing of a cystic-appearing formation (measuring 109 × 77 × 123 mm) was reported in the left adnexal region. The cyst appeared as multiloculated with internal septa and an endoluminal solid projection (characterized by post-contrastographic enhancement). (C) On sagittal viewing, the ovarian mass was responsible for the imprint on the bladder dome, without wall infiltration. There were no expansile formations in the right adnexal site. Anteverted-flexed uterus was of regular volume. No free effusion in the abdomen and no other signs of distant metastasis were reported.
Diagnostics 15 01957 g001
Figure 2. The surgical laparoscopy confirmed the presence of a mass in the left adnexa. The video of this laparoscopic procedure is in the Supplementary Material. The right adnexa, uterus, appendix, pelvic and abdominal peritoneum, and upper abdominal organs appeared normal. No bulky lymph nodes were detected. Intraoperative images of the ovarian mass: The external surface of the lesion appeared smooth, well-defined, and whitish (A,B), with reduced consistency and a cystic content (C). The maximum diameter was approximately 12 cm. The contralateral ovary and the uterus appeared normal (D).
Figure 2. The surgical laparoscopy confirmed the presence of a mass in the left adnexa. The video of this laparoscopic procedure is in the Supplementary Material. The right adnexa, uterus, appendix, pelvic and abdominal peritoneum, and upper abdominal organs appeared normal. No bulky lymph nodes were detected. Intraoperative images of the ovarian mass: The external surface of the lesion appeared smooth, well-defined, and whitish (A,B), with reduced consistency and a cystic content (C). The maximum diameter was approximately 12 cm. The contralateral ovary and the uterus appeared normal (D).
Diagnostics 15 01957 g002
Figure 3. A left adnexectomy was performed without spillage through endobag extraction and sent for frozen section analysis. The frozen section identified both cystic and solid nodules. The diagnosis of a borderline mucinous tumor within the context of a mature ovarian teratoma was made. Surgical staging was completed based on frozen section diagnosis with an appendectomy, multiple biopsies of the peritoneum and omentum, endometrial biopsies, and peritoneal washing. The final diagnosis revealed foci of low-grade mucinous carcinoma (well-differentiated–G1), associated with a mucinous borderline tumor (mBOT) and intraovarian mucin accumulation (pseudomyxoma ovarii) arising in a mature ovarian teratoma. Pseudomixoma ovarii is characterized by pools of mucin dissecting the ovarian stroma. Less commonly, in the context of ovarian mucinous tumors, it can be associated with pseudomyxoma peritonei. In the latter case, it can be challenging to distinguish from low-grade appendiceal carcinoma. Assessing the status of the appendix is mandatory in MONATs. Pseudomyxoma peritonei is characterized by the presence of mucin deposits and/or mucinous epithelium in the peritoneum, and it is usually associated with mucin-producing neoplasms, typically originating from the appendix (in 80% of cases) [16,17]. (A) Dermoid cyst (teratoma) component (H&E, original magnification 25×); (B) Mature teratoma component, showing pilosebaceous unis glands, and adipose tissue (H&E, original magnification 50×).
Figure 3. A left adnexectomy was performed without spillage through endobag extraction and sent for frozen section analysis. The frozen section identified both cystic and solid nodules. The diagnosis of a borderline mucinous tumor within the context of a mature ovarian teratoma was made. Surgical staging was completed based on frozen section diagnosis with an appendectomy, multiple biopsies of the peritoneum and omentum, endometrial biopsies, and peritoneal washing. The final diagnosis revealed foci of low-grade mucinous carcinoma (well-differentiated–G1), associated with a mucinous borderline tumor (mBOT) and intraovarian mucin accumulation (pseudomyxoma ovarii) arising in a mature ovarian teratoma. Pseudomixoma ovarii is characterized by pools of mucin dissecting the ovarian stroma. Less commonly, in the context of ovarian mucinous tumors, it can be associated with pseudomyxoma peritonei. In the latter case, it can be challenging to distinguish from low-grade appendiceal carcinoma. Assessing the status of the appendix is mandatory in MONATs. Pseudomyxoma peritonei is characterized by the presence of mucin deposits and/or mucinous epithelium in the peritoneum, and it is usually associated with mucin-producing neoplasms, typically originating from the appendix (in 80% of cases) [16,17]. (A) Dermoid cyst (teratoma) component (H&E, original magnification 25×); (B) Mature teratoma component, showing pilosebaceous unis glands, and adipose tissue (H&E, original magnification 50×).
Diagnostics 15 01957 g003
Figure 4. The cyst harbored an MBOT and a low-grade mucinous carcinoma, admixed with an extracellular mucin pool, i.e., pseudomyxoma ovarii (H&E, original magnification 25×). The carcinomatous component confidently represented the solid projection seen in the US and CT exams, as it constituted the nodular component sampled during the frozen section exam.
Figure 4. The cyst harbored an MBOT and a low-grade mucinous carcinoma, admixed with an extracellular mucin pool, i.e., pseudomyxoma ovarii (H&E, original magnification 25×). The carcinomatous component confidently represented the solid projection seen in the US and CT exams, as it constituted the nodular component sampled during the frozen section exam.
Diagnostics 15 01957 g004
Figure 5. The diagnostic workup was completed with immunohistochemistry, which showed CK7 and CDX2 immunoreactivity, with negative CK20 in the mBOT, and a CK20 focal positivity along with negative CK7 and SATB2 immunolabeling in the carcinomatous component, indicating a Müllerian/surface epithelium origin, as described in the literature [1]. Neuroendocrine markers (Chromogranin A and Synaptophysin) to rule out ovarian mucinous carcinoid [18] were negative. Ovarian mucinous borderline component (Original magnification 100×); (A) Hematoxylin and Eosin; (B) CDX2 positive; (C) CK7 positive; (D) CK20 negative.
Figure 5. The diagnostic workup was completed with immunohistochemistry, which showed CK7 and CDX2 immunoreactivity, with negative CK20 in the mBOT, and a CK20 focal positivity along with negative CK7 and SATB2 immunolabeling in the carcinomatous component, indicating a Müllerian/surface epithelium origin, as described in the literature [1]. Neuroendocrine markers (Chromogranin A and Synaptophysin) to rule out ovarian mucinous carcinoid [18] were negative. Ovarian mucinous borderline component (Original magnification 100×); (A) Hematoxylin and Eosin; (B) CDX2 positive; (C) CK7 positive; (D) CK20 negative.
Diagnostics 15 01957 g005
Figure 6. The mucinous carcinoma immunophenotype was as follows: (A) SATB2 negative, (B) CK7 negative, and (C) CK20 focally positive (Original magnification 100×). The remaining material was negative for peritoneal implant or localization. In the Table below (Table S1), we summarized the findings to provide an immunohistochemical workup if a MONAT is found in the ovary [16]. Due to the final definitive diagnosis of mucinous carcinoma, completion of surgical staging was planned with laparoscopic right adnexectomy and hysterectomy; lymphadenectomy could be considered because of the infiltrative pattern. After extensive counseling of the patient, due to the low-grade nature of the tumor itself, we decided to perform an 18F FDG PET CT scan to specifically exclude lymph nodes or other distant metastasis and eventually omit surgical lymphadenectomy. The 18FDG-PET CT scan was negative. Gastroscopy and colonoscopy were also performed to exclude other distant primary tumor sites, which yielded negative findings. A laparoscopy hysterectomy with right adnexectomy was then performed. Histological definitive diagnosis of the stadiation surgery specimen was free of tumor localization. The case was discussed during the Gynecological Oncological Multidisciplinary Tumor Board, and the patient was then sent for follow-up. A 3-month CT scan was negative for recurrence, and oncological serum markers were negative. The gynecological examination and transvaginal ultrasound were negative. Hormonal replacement therapy was prescribed, and a subsequent 3 to 4-month follow-up check was planned according to the most recent guidelines [14]. Neoplasms arising in mature cystic teratoma may present with abdominal swelling or acute abdominal pain or can be an incidental finding, as in the presented case. Histological classification may be highly challenging. We present a case where the histological differential diagnosis of mucinous lesions of the ovary was especially difficult, as it includes the entire spectrum of primary mucinous lesions (mucinous cystadenoma, mBOT, mucinous carcinoma); intestinal-type adenocarcinoma originating from intestinal-type epithelium within the teratoma; mucinous carcinoid arising from neuroendocrine cells; and metastatic mucinous neoplasia (colorectal carcinoma, mucinous lesions from the appendix) [18]. Mucinous lesions of Müllerian or surface epithelial origin typically show CK7 positivity and variable CK20 expression (ranging from negative to positive and from focal to diffuse), but are consistently negative for SATB2 [1,13]. SATB2 positivity can help identify the gastroenteric phenotype, and the differential diagnosis should account for intestinal-type adenocarcinoma arising from intestinal-type teratomatous epithelium or metastasis from the lower gastrointestinal tract. The diagnostic evaluation of these diverse yet histologically similar lesions must always consider the possibility of a metastatic origin, along with the clinical context. However, clinical features may not always be present, as we described in the current case report. The surgical decision to complete the assessment of the origin of mucinous neoplasms cannot be made in the intraoperative setting, as we have illustrated; the overlap of different lesions originating from various sites is very high. In the present case, the clinical and histological features concurred in defining the final diagnosis. It is pivotal to remember that patients with teratoma-associated mucinous tumors are reported to be younger than those with non-teratoma-associated mucinous neoplasms and other ovarian cancer histotypes, such as serous, endometrioid, and clear cell carcinomas [1]. In the present case, preoperative imaging led to the hypothesis of borderline/malignant nature of the lesion, highlighting the need for an expert ultrasonographer and a specialized radiologist. Teratomas are frequent findings in young patients, and malignant lesions arising in this context are rare and usually microscopic. Not all ovarian teratomas need to be surgically treated to eradicate or diagnose a potential malignant lesion. Patients at risk may be adequately identified through high-quality imaging, such as expert transvaginal ultrasound and a thorough clinical examination. No specific ultrasound signs have yet been proposed for the identification of teratoma-associated tumors; however, dimension, vascularization, and the presence of a solid component may lead to a diagnostic hypothesis. Initial surgical evaluation and a two-step surgery plan may be helpful in management: immunohystochemistry, specific diagnosis among the previouslt described wide spectrum of mucinous teratoma-associated and non-associated ovarian tumors, and their specific growth pattern can be reached only after definitive pathological evaluation and not on frozen section. Since patients affected by teratomas and teratoma-associated tumors are often young and of childbearing age, indications for surgical staging and treatment may change after final histology, such as for fertility sparing treatment if possible. Follow-up must subscribe to mucinous tumor follow-up guidelines [19]. Moreover, we showed how much preoperative diagnosis of ovarian masses may be highly challenging, and most patients are diagnosed only after pathological and immunohistochemical evaluations and a thorough differential diagnostic workup. Early detection and timely management remain crucial to improving patient outcomes. With the increasing number of reported cases, radiologists, pathologists, and clinicians must be aware of the potential for malignant transformation in typical teratomatous contexts.
Figure 6. The mucinous carcinoma immunophenotype was as follows: (A) SATB2 negative, (B) CK7 negative, and (C) CK20 focally positive (Original magnification 100×). The remaining material was negative for peritoneal implant or localization. In the Table below (Table S1), we summarized the findings to provide an immunohistochemical workup if a MONAT is found in the ovary [16]. Due to the final definitive diagnosis of mucinous carcinoma, completion of surgical staging was planned with laparoscopic right adnexectomy and hysterectomy; lymphadenectomy could be considered because of the infiltrative pattern. After extensive counseling of the patient, due to the low-grade nature of the tumor itself, we decided to perform an 18F FDG PET CT scan to specifically exclude lymph nodes or other distant metastasis and eventually omit surgical lymphadenectomy. The 18FDG-PET CT scan was negative. Gastroscopy and colonoscopy were also performed to exclude other distant primary tumor sites, which yielded negative findings. A laparoscopy hysterectomy with right adnexectomy was then performed. Histological definitive diagnosis of the stadiation surgery specimen was free of tumor localization. The case was discussed during the Gynecological Oncological Multidisciplinary Tumor Board, and the patient was then sent for follow-up. A 3-month CT scan was negative for recurrence, and oncological serum markers were negative. The gynecological examination and transvaginal ultrasound were negative. Hormonal replacement therapy was prescribed, and a subsequent 3 to 4-month follow-up check was planned according to the most recent guidelines [14]. Neoplasms arising in mature cystic teratoma may present with abdominal swelling or acute abdominal pain or can be an incidental finding, as in the presented case. Histological classification may be highly challenging. We present a case where the histological differential diagnosis of mucinous lesions of the ovary was especially difficult, as it includes the entire spectrum of primary mucinous lesions (mucinous cystadenoma, mBOT, mucinous carcinoma); intestinal-type adenocarcinoma originating from intestinal-type epithelium within the teratoma; mucinous carcinoid arising from neuroendocrine cells; and metastatic mucinous neoplasia (colorectal carcinoma, mucinous lesions from the appendix) [18]. Mucinous lesions of Müllerian or surface epithelial origin typically show CK7 positivity and variable CK20 expression (ranging from negative to positive and from focal to diffuse), but are consistently negative for SATB2 [1,13]. SATB2 positivity can help identify the gastroenteric phenotype, and the differential diagnosis should account for intestinal-type adenocarcinoma arising from intestinal-type teratomatous epithelium or metastasis from the lower gastrointestinal tract. The diagnostic evaluation of these diverse yet histologically similar lesions must always consider the possibility of a metastatic origin, along with the clinical context. However, clinical features may not always be present, as we described in the current case report. The surgical decision to complete the assessment of the origin of mucinous neoplasms cannot be made in the intraoperative setting, as we have illustrated; the overlap of different lesions originating from various sites is very high. In the present case, the clinical and histological features concurred in defining the final diagnosis. It is pivotal to remember that patients with teratoma-associated mucinous tumors are reported to be younger than those with non-teratoma-associated mucinous neoplasms and other ovarian cancer histotypes, such as serous, endometrioid, and clear cell carcinomas [1]. In the present case, preoperative imaging led to the hypothesis of borderline/malignant nature of the lesion, highlighting the need for an expert ultrasonographer and a specialized radiologist. Teratomas are frequent findings in young patients, and malignant lesions arising in this context are rare and usually microscopic. Not all ovarian teratomas need to be surgically treated to eradicate or diagnose a potential malignant lesion. Patients at risk may be adequately identified through high-quality imaging, such as expert transvaginal ultrasound and a thorough clinical examination. No specific ultrasound signs have yet been proposed for the identification of teratoma-associated tumors; however, dimension, vascularization, and the presence of a solid component may lead to a diagnostic hypothesis. Initial surgical evaluation and a two-step surgery plan may be helpful in management: immunohystochemistry, specific diagnosis among the previouslt described wide spectrum of mucinous teratoma-associated and non-associated ovarian tumors, and their specific growth pattern can be reached only after definitive pathological evaluation and not on frozen section. Since patients affected by teratomas and teratoma-associated tumors are often young and of childbearing age, indications for surgical staging and treatment may change after final histology, such as for fertility sparing treatment if possible. Follow-up must subscribe to mucinous tumor follow-up guidelines [19]. Moreover, we showed how much preoperative diagnosis of ovarian masses may be highly challenging, and most patients are diagnosed only after pathological and immunohistochemical evaluations and a thorough differential diagnostic workup. Early detection and timely management remain crucial to improving patient outcomes. With the increasing number of reported cases, radiologists, pathologists, and clinicians must be aware of the potential for malignant transformation in typical teratomatous contexts.
Diagnostics 15 01957 g006

Supplementary Materials

The following supporting information can be downloaded at: https://zenodo.org/records/15801336. accessed on 27 July 2025. Video description: This supplementary video shows a laparoscopic procedure performed for the evaluation of an ovarian mass. The surgical steps include left salpingo-oophorectomy, appendectomy, peritoneal biopsies, and omental biopsy. The procedure is part of the diagnostic workup of a suspected ovarian neoplasm. https://zenodo.org/records/16737108. accessed on 27 July 2025. Table S1, describes the immunohistochemical findings in ovarian mucinous neoplasia.

Author Contributions

Conceptualization, C.G.; methodology, M.M.; writing—original draft preparation, C.G.; writing—review and editing, C.G., L.M., C.A., and F.M.; supervision, D.M., G.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Ramalingam, P.; Marques-Piubelli, M.L.; Alvarado-Cabrero, I.; Montiel, M.D.P.; Tandon, N.; Euscher, E.D.; Malpica, A. Mucinous neoplasms associated with mature cystic teratomas: A clinicopathologic study of 50 cases: Are we ready for nomenclature change? Ann. Diagn. Pathol. 2025, 78, 152494. [Google Scholar] [CrossRef] [PubMed]
  2. Atwi, D.; Kamal, M.; Quinton, M.; Hassell, L.A. Malignant transformation of mature cystic teratoma of the ovary. J. Obstet. Gynaecol. Res. 2022, 48, 3068–3076. [Google Scholar] [CrossRef] [PubMed]
  3. Li, C.; Zhang, Q.; Zhang, S.; Dong, R.; Sun, C.; Qiu, C.; Zhang, Z.; Yang, X.; Kong, B. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: A systematic review. BMC Cancer 2019, 19, 217. [Google Scholar] [CrossRef] [PubMed]
  4. Cooke, S.L.; Ennis, D.; Evers, L.; Dowson, S.; Chan, M.Y.; Paul, J.; Hirschowitz, L.; Glasspool, R.M.; Singh, N.; Bell, S.; et al. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. Clin. Cancer Res. 2017, 23, 7633–7640. [Google Scholar] [CrossRef] [PubMed]
  5. Chao, A.; Lai, C.H.; Chao, A.S.; Lin, C.Y.; Wang, Y.C.; Huang, H.J.; Wu, R.C. Molecular characterization of ovarian squamous cell carcinoma originating from mature teratoma. J. Mol. Med. 2025, 103, 101–111. [Google Scholar] [CrossRef] [PubMed]
  6. Choi, W.K.; Lee, D.H.; Cho, D.H.; Jang, K.Y.; Kim, K.M. Primary malignant melanoma arising from ruptured ovarian mature cystic teratoma with elevated serum CA 19-9: A case report and review of literature. BMC Womens Health 2019, 19, 149. [Google Scholar] [CrossRef] [PubMed]
  7. Murray, J.; McIlwaine, P.; Morrison, P.J.; McCluggage, W.G. Sebaceous Carcinoma Arising in Ovarian Teratoma: First Report Associated With Germline Mismatch Repair Gene Mutation. Int. J. Gynecol. Pathol. 2022, 41, 608–614. [Google Scholar] [CrossRef] [PubMed]
  8. Balakrishnan, R.; Oren, N.C.; Kertowidjojo, E.C. Low-grade mucinous neoplasm arising from mature ovarian teratoma with pseudomyxoma peritonei. Int. J. Gynecol. Cancer 2023, 33, 1005–1006. [Google Scholar] [CrossRef] [PubMed]
  9. Vang, R.; Gown, A.M.; Zhao, C.; Barry, T.S.; Isacson, C.; Richardson, M.S.; Ronnett, B.M. Ovarian mucinous tumors associated with mature cystic teratomas: Morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am. J. Surg. Pathol. 2007, 31, 854–869. [Google Scholar] [CrossRef] [PubMed]
  10. Ronnett, B.M.; Seidman, J.D. Mucinous tumors arising in ovarian mature cystic teratomas: Relationship to the clinical syndrome of pseudomyxoma peritonei. Am. J. Surg. Pathol. 2003, 27, 650–657. [Google Scholar] [CrossRef] [PubMed]
  11. Simons, M.; Simmer, F.; Bulten, J.; Ligtenberg, M.J.; Hollema, H.; van Vliet, S.; de Voer, R.M.; Kamping, E.J.; van Essen, D.F.; Ylstra, B.; et al. Two types of primary mucinous ovarian tumors can be distinguished based on their origin. Mod. Pathol. 2020, 33, 722–733. [Google Scholar] [CrossRef] [PubMed]
  12. Stewart, C.J.; Ardakani, N.M.; Doherty, D.A.; Young, R.H. An evaluation of the morphologic features of low-grade mucinous neoplasms of the appendix metastatic in the ovary, and comparison with primary ovarian mucinous tumors. Int. J. Gynecol. Pathol. 2014, 33, 1–10. [Google Scholar] [CrossRef] [PubMed]
  13. Stewart, C.J.; Tsukamoto, T.; Cooke, B.; Leung, Y.C.; Hammond, I.G. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: Report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour. Pathology 2006, 38, 534–538. [Google Scholar] [CrossRef] [PubMed]
  14. Ledermann, J.; Matias-Guiu, X.; Amant, F.; Concin, N.; Davidson, B.; Fotopoulou, C.; González-Martin, A.; Gourley, C.; Leary, A.; Lorusso, D.; et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease. Ann. Oncol. 2024, 35, 248–266. [Google Scholar] [CrossRef] [PubMed]
  15. Timmerman, D.; Planchamp, F.; Bourne, T.; Landolfo, C.; du Bois, A.; Chiva, L.; Cibula, D.; Concin, N.; Fischerova, D.; Froyman, W.; et al. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int. J. Gynecol. Cancer 2021, 31, 961–982. [Google Scholar] [CrossRef] [PubMed]
  16. Nucci, M.R.; Oliva, E. Gynecological, 3rd ed.; Elsevier: Amsterdam, The Netherlands, 2024. [Google Scholar]
  17. Ionescu, S.; Marincas, M.; Madge, O.L.; Dicu-Andreescu, I.G.; Chitoran, E.; Rotaru, V.; Cirimbei, C.; Gherghe, M.; Ene, A.; Rosca, R.; et al. Ovarian Causes of Pseudomyxoma Peritonei (PMP)—A Literature Review. Cancers 2024, 16, 1446. [Google Scholar] [CrossRef] [PubMed]
  18. Kim, N.R.; Ha, S.Y.; Shin, J.W.; Lim, S.; Park, C.Y.; Cho, H.Y. Primary ovarian mixed strumal and mucinous carcinoid arising in an ovarian mature cystic teratoma. J. Obs. Gynaecol. Res. 2016, 42, 211–216. [Google Scholar] [CrossRef] [PubMed]
  19. Morice, P.; Scambia, G.; Abu-Rustum, N.R.; Acien, M.; Arena, A.; Brucker, S.; Cheong, Y.; Collinet, P.; Fanfani, F.; Filippi, F.; et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: Guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol. 2024, 25, e602–e610. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Giacometti, C.; Mirandola, M.; Aliberti, C.; Molinari, F.; Marcolini, L.; Mautone, D.; Martignoni, G. Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum. Diagnostics 2025, 15, 1957. https://doi.org/10.3390/diagnostics15151957

AMA Style

Giacometti C, Mirandola M, Aliberti C, Molinari F, Marcolini L, Mautone D, Martignoni G. Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum. Diagnostics. 2025; 15(15):1957. https://doi.org/10.3390/diagnostics15151957

Chicago/Turabian Style

Giacometti, Cinzia, Mariateresa Mirandola, Camillo Aliberti, Filippo Molinari, Lisa Marcolini, Daniele Mautone, and Guido Martignoni. 2025. "Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum" Diagnostics 15, no. 15: 1957. https://doi.org/10.3390/diagnostics15151957

APA Style

Giacometti, C., Mirandola, M., Aliberti, C., Molinari, F., Marcolini, L., Mautone, D., & Martignoni, G. (2025). Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum. Diagnostics, 15(15), 1957. https://doi.org/10.3390/diagnostics15151957

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop